Last reviewed · How we verify
Biohaven Therapeutics Ltd. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
3 Phase 2
4 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| BHV-4157 | BHV-4157 | phase 3 | 5-HT1F receptor agonist | 5-HT1F receptor | Neurology |
Therapeutic area mix
- Neurology · 4
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- AbbVie · 1 shared drug class
- Allergan · 1 shared drug class
- Amgen · 1 shared drug class
- Merck Sharp & Dohme LLC · 1 shared drug class
- NuPathe Inc. · 1 shared drug class
- Pfizer · 1 shared drug class
- Pfizer Inc. · 1 shared drug class
- Samsung Medical Center · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Biohaven Therapeutics Ltd.:
- Biohaven Therapeutics Ltd. pipeline updates — RSS
- Biohaven Therapeutics Ltd. pipeline updates — Atom
- Biohaven Therapeutics Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Biohaven Therapeutics Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/biohaven-therapeutics-ltd. Accessed 2026-05-16.